- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE Healthcare Launches Omni Legend PET/CT System at EANM Congress
The inclusion of digital bismuth germanate (BGO) detector material with the Omni Legend system reportedly more than doubles the sensitivity of older PET/CT devices, improves scan times, and enhances the detection of small lesions.
Emphasizing enhanced diagnostic capabilities, improved efficiency and artificial intelligence (AI)-enabled features, GE Healthcare introduced the Omni Legend positron emission tomography/computed tomography (PET/CT) platform at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona, Spain.
GE Healthcare said a key feature of the Omni Legend system is the enhanced sensitivity with the small crystal size of the digital bismuth germanate (BGO) detector. The PET/CT platform reportedly bolsters image quality with Precision DL, a deep neural network that facilitates improved qualitative accuracy and contrast-to-noise ratio.
“Sensitivity and image quality are everything in PET/CT. Omni Legend delivers on both — meeting all our image quality criteria for oncology and providing impressive sensitivity to image high-count tracers for cardiac and neuroimaging, which helps better inform patient diagnoses and monitoring,” noted John Kennedy, Ph.D., a chief physicist in the Nuclear Medicine Department at the Rambam Health Care Campus in northern Israel.
Dr. Kennedy said the Omni Legend PET/CT system enabled his facility to reduce dosing by 40 percent in comparison to previous PET/CT devices and perform up to 35 patient scans in a 9.5-hour shift.
The Omni Legend system also allows hands-free patient positioning with the AI-powered Auto Positioning feature, according to GE Healthcare.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
